MOXIFLOXACIN TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
19-02-2021
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
Tilgængelig fra:
PRO DOC LIMITEE
ATC-kode:
J01MA14
INN (International Name):
MOXIFLOXACIN
Dosering:
400MG
Lægemiddelform:
TABLET
Sammensætning:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
Indgivelsesvej:
ORAL
Enheder i pakken:
30
Recept type:
Prescription
Terapeutisk område:
QUINOLONES
Produkt oversigt:
Active ingredient group (AIG) number: 0142242001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2017-04-12
Produktets egenskaber
Page 1 of 67
PRODUCT MONOGRAPH
PR
MOXIFLOXACIN
Moxifloxacin Tablets
400 mg Moxifloxacin (as moxifloxacin hydrochloride)
House Standard
Antibacterial Agent
PRO DOC LTÉE
2925 boul. Industriel
Laval, Québec
H7L 3W9
Date of Revision:
February 19, 2021.
SUBMISSION CONTROL NO:
248826
Page 2 of 67
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
6
ADVERSE REACTIONS
.................................................................................................
14
DRUG INTERACTIONS
.................................................................................................
18
DOSAGE AND ADMINISTRATION
.............................................................................
20
OVERDOSAGE
...............................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 22
STORAGE AND STABILITY
.........................................................................................
29
SPECIAL HANDLING INSTRUCTIONS
......................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 30
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.........................................................................
31
CLINICAL TRIALS
........................................................................................
Læs hele dokumentet
